But competition is actually most central to innovation--and the opposite of what Big Pharma wants.
So we owe it to the American people, and I will be doing everything I can in my power to do so.
Product hopping or evergreening is the reformulation of a drug by a brand-name manufacturer to delay competition and protect protection for ...
Competition is crucial to lowering prescription drug prices and improving America's access to lifesaving medication.
We can't leave any stone unturned in examining ways to address this issue.
I am proud to preside over this hearing in the Consumer Protection Subcommittee because Congress must take direct action to protect American...
competition is actually more central to innovation, and the opposite of what Big Pharma wants.
But whatever the word or phrase, the bottom line is: drug manufacturers are gaming the system to make more money at consumers' expense.
We are not making progress. We are actually going backwards.
the talk is not going to solve the problem. And any of the ideas that you have that we have heard today could be very useful.
My sense of innovation is when there is regulation, industry responds and finds a way to do it.